Yong Yang

Yong Yang

Auto-generated profile, based on publicly available information

Yong Yang

General Hospital of Ningxia Medical University

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Medicine
Verified
Journal Article
Open access
NWNing Wang
Ning Wang
XXXiaojiang Xiong
Xiaojiang Xiong
LXLixin Xu
Lixin Xu
MJMing Ji
Ming Ji
TYTao Yang
Tao Yang
HCHongxia Chen
Hongxia Chen
Background: The purpose of this study was to assess the cost benefit and transfusions of oral and IV tranexamic acid (TXA) in primary total hip arthroplasty (THA). Methods: PubMed, Embase, Web of Science, and the Cochrane Library were systematically searched for randomized controlled trials (RCTs) comparing oral and IV TXA in primary THA. Primary outcomes were total blood loss, maximum hemoglobin drop, transfusion requirements, and cost benefit. Secondary outcomes were length of stay, deep venous thrombosis (DVT) and/or pulmonary embolism (PE). Results: Four independent RCTs were included involving 391 patients. There was no difference in the total blood loss (P = .99), maximum hemoglobin drop (P = .73), and the length of stay (P = .95) between the 2 groups. Transfusion requirements (P = .97) were similar. The total mean cost was the US $75.41 in oral TXA group and the US $580.83 in IV TXA group. The incidence of DVT (P = .3) did not differ significantly between the 2 groups, and no PE was reported in all studies. Conclusion: Oral TXA shows similar efficacy and safety as IV TXA in reducing total blood loss, maximum hemoglobin drop and transfusion requirements in primary THA. However, oral TXA may be more cost-benefit than IV TXA. Level of Evidence: Level I, therapeutic study.

13 September 2019 in Records of Natural Products
Verified
Journal Article
Closed access
YYYong Yang
Yong Yang
TYTian Yaping
Tian Yaping
QZQinghe Zhang
Qinghe Zhang
XLXiaoqing Li
Xiaoqing Li
YFYun Fu
Yun Fu
DLDan Lu
Dan Lu
Fructus Sophorae (FS), the dry mature fruit of Sophora japonica Leguminosae, is a valuable traditional Chinese medicine resource with flavonoids as the major active ingredients. To identify the plant-derived estrogen-like flavonoids serving as potential osteoporosis chemopreventive agents, we isolated and identified 27 flavonoids compounds, including 17 compounds obtained for the first time from FS. To screen out the flavonoids with estrogen-like biological behavior from the 11 high yield compounds, we set up an in vitro screening system in rat osteoblast MC3T3-E1 cells including MTT assay, alkaline phosphatase staining and Alizarin red S staining assay to examine the effects on cell proliferation, differentiation and mineralization of osteoblast cells respectively. Six flavonoids, including genistein, sophoricoside, sophorabioside, sophoraflavonoloside, nicotiflorin and rutin, significantly increased the cellular activity of MC3T3-E1 cells. Furthermore, blocking the estrogen receptor signaling by tamoxifen compromised the effects above significantly, suggesting the 6 compounds behave as estrogen-like reagents. Moreover, the interaction between the six flavonoids from FS and estrogen receptor was clarified by molecular docking method from Glide XP. Collectively, being used as food and medicine in China, FS is rich in flavonoids with estrogen-like effects, may be used as healthy supplementary in treating postmenopausal women osteoporosis.

8 May 2021 in Records of Natural Products
Verified
Journal Article
Closed access
MZMojiao Zhao
Mojiao Zhao
CZChao Zhang
Chao Zhang
DZDong Zhang
Dong Zhang
SZSiyu Zhu
Siyu Zhu
TLTianjiao Liu
Tianjiao Liu
YYYong Yang
Yong Yang
Inhibition of protein disulfide isomerase (PDI) has been attempted as a promising anti-cancer strategy. However, there is still no currently available PDI inhibitors approved for clinical use. Here, we isolated seven high yield alkaloids from Stephaniae tetrandrae Radix (STR), a medical herb frequently prescribed in anti-tumor condition, and identified two potent natural PDI inhibitors, dicentrine and dicentrinone. Among the seven alkaloids isolated, dicentrinone (1), dicentrine (2), tetrandrine (4), and fangchinoline (5) could significantly reduce cell viability in a dosage dependent manner detected by MTT assay in human hepatoma cells. To examine whether the candidate compounds are potent PDI inhibitors, we performed insulin turbidity assay and found dicentrine and dicentrinone, but not tetrandrine and fangchinoline, could effectively inhibit PDI activity, with IC50 of 56.70 μM and 43.95 μM respectively. Meanwhile, dicentrine and dicentrinone failed to further reduce the cell number index when co-treated with siRNA of PDI, suggesting the compounds behave as PDI inhibitors. Furthermore, dicentrinone and dicentrine have been successfully docked to the active pocket of PDI (PDB #3UEM) by molecular docking, suggesting the existence of physical interaction between compounds and PDI. Our results suggested that dicentrine and dicentrinone may be developed into safe PDI inhibitors.

12 January 2026 in Records of Natural Products
Verified
Journal Article
Closed access
YYYong Yang
Yong Yang
JLJianning Li
Jianning Li
NYNing Yan
Ning Yan
LLLei Liu
Lei Liu
XYXiaoyan Yang
Xiaoyan Yang
ZSZhijun Song
Zhijun Song
Marine-derived fungi have been regarded as rich and reliable sources of biologically active and chemically novel compounds, which may both directly and indirectly be used as potential lead compounds for drug research and development. In this study, one new discovered 2-pyridone derivative, penicinine C (1), a new phenylhydrazone derivative, penicinine D (2), together with four known compounds, (14β, 22E)-9,14-dihydroxyergosta-4,7,22-triene-3,6-dione (3), ergochrome F (4), nafuredin A (5) and altenusin (6) were isolated and purified from a marine-derived fungus Penicillium sp. MF20218001. Their chemical structures were elucidated through detailed 1D/2D NMR and HRESIMS spectroscopic analysis, computational calculation methods and comparison with previously reported data. Bioactivity assays showed that compounds 1 and 5 exhibited weak activity against Candida albicans with minimum inhibitory concentrations of 50 and 25 μg/mL, respectively.